For the quarter ending 2026-03-31, NAMSW made $3,040K in revenue. -$49,013K in net income. Net profit margin of -1612.27%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Revenue | 3,040 | 21,459* | 348 | |
| Research and development expenses | 38,009 | 45,922* | 30,971 | |
| Selling, general and administrative expenses | 23,451 | 32,794* | 24,520 | |
| Total operating expenses | 61,460 | 78,716* | 55,491 | |
| Operating loss | -58,420 | -57,257* | -55,143 | |
| Interest income | 5,650 | 7,453* | 6,713 | |
| Fair value change - earnout | - | -998* | - | |
| Fair value change - warrants | -5,942 | -48,601* | 23,792 | |
| Loss on disposal of property, plant and equipment | - | - | -1 | |
| Foreign exchange gains/(losses) | -1,613 | 12,401* | 218 | |
| Gain before tax | -48,441 | 12,196 | -72,005 | |
| Gain for the year | -48,441 | 12,196* | -72,005 | |
| Unrealized loss/(gain) on available-for-sale securities, net of tax | -572 | -613* | 313 | |
| Total comprehensive gain for the year, net of tax | -49,013 | 11,583 | -71,692 | |
| Basic EPS | -0.4 | 0.098 | -0.61 | |
| Diluted EPS | -0.4 | 0.098 | -0.61 | |
| Basic Average Shares | 121,716,006 | 117,848,196 | 119,000,266 | |
| Diluted Average Shares | 121,716,006 | 117,848,196 | 119,000,266 | |
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)